Oncoinvent ASA

Share Issue/Capital Change • Dec 8, 2025

Oncoinvent ASA: Notification of trade - primary insider/close associate

Oncoinvent ASA: Notification of trade - primary insider/close associate

8 December 2025: Reference is made to the stock exchange announcements published

by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and

subsequent announcements, regarding the fully underwritten rights issue of

260,000,000 new shares in the Company (the "Offer Shares") raising gross

proceeds of NOK 130 million (the "Rights Issue"). Further, reference is made to

the stock exchange announcement published by the Company on 5 December 2025

regarding the resolution by the board of directors of the Company to issue

31,199,997 new shares in the Company, each with a nominal value of NOK 0.50, at

a subscription price of NOK 0.50 per share (the "Underwriting Commission

Shares") to be delivered to the underwriters pursuant to the subscription and

underwriting agreements dated 30 June 2025 as settlement of their entitlement to

an underwriting fee under said agreements.

Please see the attached notifications of trade for information regarding the

allocation and subscription of Underwriting Commission Shares by certain primary

insiders and their close associates.

***

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian

Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel

radiopharmaceutical therapies against cancer. The lead product candidate,

Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting

micro-metastases post-surgery, harnessing the benefits of modern

radiopharmaceuticals without the complexities of biological targeting.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical

development program in two indications. One Phase 1 trial and one Phase 1/2a

trial have been completed and one randomized Phase 2 trial is currently ongoing

in the US, UK and Europe. Early clinical efficacy data are highly encouraging,

and no serious toxicity or safety concerns have been reported to date. The

Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art

manufacturing facility to produce drug products for clinical trials in Nydalen,

Oslo. Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local

treatment of cancer that has spread to body cavities. It consists of calcium

carbonate microparticles containing the radioactive material radium-224. The

mode of action is the decay of radium-224 emitting alpha-particles, a highly

potent form of ionizing radiation. Radspherin® is investigated in clinical

studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer

and it is administered intraperitoneally after surgical resection with removal

of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press

release are forward-looking statements and are not a representation that

Oncoinvent's plans, estimates, or expectations will be achieved. These forward

-looking statements represent Oncoinvent's expectations as of the date of this

press release, and Oncoinvent disclaims any obligation to update the forward

-looking statements. These forward-looking statements are subject to known and

unknown risks and uncertainties that may cause actual results to differ

materially, including with respect to whether the results of clinical or other

studies will support the use of our product offerings, the impact of results of

such studies, our expectations of the reliability, accuracy and performance of

our tests, or of the benefits of our tests and product offerings to patients,

providers and payers.